Neuroprotection of nalmefene for postoperative patients with spontaneous intracerebral hemorrhage

References

• Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450–60.
   PubMed Web of Science ®Google Scholar
• van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-analysis. Lancet Neurol 2010;9:167–76.
   PubMed Web of Science ®Google Scholar
• Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol 2005;4:662–72.
   PubMed Web of Science ®Google Scholar
• Brunswick AS, Hwang BY, Appelboom G, et al.. Serum biomarkers of spontaneous intracerebral hemorrhage induced secondary brain injury. J Neurol Sci 2012;321:1–10.
   PubMed Web of Science ®Google Scholar
• Olney JW. Excitotoxicity: An overview. Can Dis Wkly Rep 1990;16(Suppl 1E):47–57; discussion 57–48.
   PubMedGoogle Scholar
• Herman BH, Goldstein A. Antinociception and paralysis induced by intrathecal dynorphin a. J Pharmacol Exp Ther 1985;232:27–32.
   PubMed Web of Science ®Google Scholar
• Krumins SA, Faden AI. Traumatic injury alters opiate receptor binding in rat spinal cord. Ann Neurol 1986;19:498–501.
   PubMed Web of Science ®Google Scholar
• Faden AI, Molineaux CJ, Rosenberger JG, et al.. Increased dynorphin immunoreactivity in spinal cord after traumatic injury. Regul Pept 1985;11:35–41.
   PubMed Web of Science ®Google Scholar
• Scavini C, Rozza A, Bo P, et al. Kappa-opioid receptor changes and neurophysiological alterations during cerebral ischemia in rabbits. Stroke 1990;21:943–7.
   PubMed Web of Science ®Google Scholar
• Sharma HS, Nyberg F, Gordh T, et al. Topical application of dynorphin a (1–17) antibodies attenuates neuronal nitric oxide synthase up-regulation, edema formation, and cell injury following focal trauma to the rat spinal cord. Acta Neurochir Suppl 2006;96:309–15.
   PubMedGoogle Scholar
• Sharma HS, Patnaik R, Patnaik S, et al. Antibodies to dynorphin a (1–17) attenuate closed head injury induced blood–brain barrier disruption, brain edema formation and brain pathology in the rat. 2010;106:301–6.
   Google Scholar
• Faden AI, Jacobs TP, Holaday JW. Opiate antagonist improves neurologic recovery after spinal injury. Science 1981;211: 493–4.
   PubMed Web of Science ®Google Scholar
• Hayes RL, Galinat BJ, Kulkarne P, et al. Effects of naloxone on systemic and cerebral responses to experimental concussive brain injury in cats. J Neurosurg 1983;58:720–8.
   PubMed Web of Science ®Google Scholar
• Federico F, Lucivero V, Lamberti P, et al. A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke. Ital J Neurol Sci 1991;12:557–63.
   PubMedGoogle Scholar
• Perraro F, Tosolini G, Pertoldi F, et al. Double-blind placebo-controlled trial of naloxone on motor deficits in acute cerebrovascular disease. Lancet 1984;1:915.
   PubMed Web of Science ®Google Scholar
• Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985;7:175–7.
   PubMed Web of Science ®Google Scholar
• Faden AI, Sacksen I, Noble LJ. Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism. J Pharmacol Exp Ther 1988;245:742–8.
   PubMed Web of Science ®Google Scholar
• Vink R, McIntosh TK, Rhomhanyi R, et al. Opiate antagonist nalmefene improves intracellular free mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats. J Neurosci 1990;10:3524–30.
   PubMed Web of Science ®Google Scholar
• Faden AI, Shirane R, Chang LH, et al. Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. J Pharmacol Exp Ther 1990;255:451–8.
   PubMed Web of Science ®Google Scholar
• Hu SK, Huang FP, Zheng K. Brain protective efficacy of nalmefene for patients with brain tumor undergone operation. J Int Neurol Neurosurg 2011; 38(4):319–22.
   Google Scholar
• Wang HL, Liu HT, Yu KJ. Clinical study of nalmefene in acute severe traumatic brain injury. Chin J Crit Care Med 2011;31(8):740–2.
   Google Scholar
• Clark WM, Raps EC, Tong DC, et al. Cervene (nalmefene) in acute ischemic stroke : Final results of a phase iii efficacy study. The cervene stroke study investigators. Stroke 2000;31: 1234–9.
   PubMed Web of Science ®Google Scholar
• Konieczko KM, Jones JG, Barrowcliffe MP, et al. Antagonism of morphine-induced respiratory depression with nalmefene. Br J Anaesth 1988;61:318–23.
   PubMed Web of Science ®Google Scholar
• Morgenstern LB, Hemphill JC, 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2010;41:2108–29.
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
   PubMed Web of Science ®Google Scholar
• Li JZ, Nong SH, Huang ZH, et al. Study of β-endophrin and dynophrin levels in the patients with traumatic brain injury. Chin J Crit Care Med 2010;30(3):227–9.
   Google Scholar
• Zhang GJ, Zhu C, Jiang JY, et al. Alteration of β-endophrin level after traumatic brain injury. Chinese Journal of Traumatology 1991;7(supple):24–6.
   Google Scholar
• Li XY. Nalmefene for the patients received neurosurgery after general anesthesia. China Pharmaceuticals 2012;21(9):83–4.
   Google Scholar
• Calvanio R, Burke DT, Kim HJ, et al. Naltrexone: Effects on motor function, speech, and activities of daily living in a patient with traumatic brain injury. Brain Inj 2000;14:933–42.
   PubMed Web of Science ®Google Scholar
• Clark W, Ertag W, Orecchio E, et al. Cervene in acute ischemic stroke: Results of a double-blind, placebo-controlled, dose-comparison study. J Stroke Cerebrovasc Dis 1999;8:224–30.
   PubMedGoogle Scholar
• Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke : Possible neurotoxic effects of an nmda antagonist. Stroke 2000;31:347–54.
   PubMed Web of Science ®Google Scholar
• Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (gain international) in patients with acute stroke: A randomised controlled trial. Gain international investigators. Lancet 2000;355:1949–54.
   PubMed Web of Science ®Google Scholar
• Sareen D. Neuroprotective agents in acute ischemic stroke. J Assoc Physicians India 2002;50:250–8.
   PubMedGoogle Scholar
• He M, Guan XL, Wang ML. Change of opioid peptide content in plasma and CSF of patients with cerebral hemorrhage and interference effect of naloxone. J Clin Neurol 2006;19(3):182–4.
   Google Scholar